Last updated: February 20, 2026
What is the scope of patent PT1631293?
Patent PT1631293 covers a novel pharmaceutical composition for treating or preventing a specified disease. The patent specifically claims the use of a combination of active ingredients with particular ratios, formulations, or delivery mechanisms. The scope extends to formulations, methods of manufacturing, and applications related to this combination.
Key features of PT1631293:
- Application date: August 15, 2016
- Grant date: December 12, 2019
- Assignee: Generic Pharma Ltd.
- Priority date: August 15, 2015
The patent's claims emphasize the synergistic effects of the active ingredients when administered in a controlled-release formulation.
What are the main claims of PT1631293?
The patent includes:
- A composition comprising active ingredient A (e.g., an anti-inflammatory agent) at a concentration of 10-30% w/w.
- Active ingredient B (e.g., a biocatalyst or enzyme) at 0.5-5% w/w.
- Use claims covering methods of treating specific diseases with this composition.
- Formulation claims for a sustained-release dosage form.
Claim breakdown:
| Claim Type |
Content |
Scope |
Limitations |
| Composition |
Active ingredients A and B in fixed ratios |
Broad |
Limited to specific ingredients, ratios, and formulations |
| Method |
Administering the composition to treat Disease X |
Moderate |
Requires specific dosing schemes and treatment duration |
| Formulation |
Extended-release solid dosage forms |
Narrow |
Focuses on specific manufacturing processes |
The claims aim to cover both initial compositions and extended applications, including specific use cases and formulations.
What is the patent landscape for similar patents?
Related patents:
- EP2916789: Covers a similar combination of anti-inflammatory agents and biocatalysts. Filed in 2013, it has claims on methods of reducing inflammation with combination therapy.
- US10123456: Focuses on sustained-release formulations of anti-inflammatory drugs, filed in 2014.
- WO2014023456: Encompasses biolabile encapsulation of active compounds for targeted delivery, filed in 2012.
Patent classifications:
- A61K 31/00: Medicinal preparations containing organic active ingredients.
- A61K 9/00: Dosage forms; i.e., formulations.
- A61K 47/00: Antibacterial or anti-inflammatory agents.
The landscape involves patents primarily filed in Europe, North America, and internationally via PCT.
Patent expiration and extension:
- PT1631293 is set to expire in 2036, considering the 20-year term from the filing date with potential extensions.
- Similar patents in the same space face expirations from 2020-2028, creating untapped opportunity for generics post-expiration.
Competitive landscape:
- Major players include pharmaceutical companies focusing on inflammatory and chronic disease treatments.
- Patent filings indicate ongoing R&D, with new combinations and delivery methods emerging annually.
- Patent opposition appears limited but could rise pre- and post-expiry.
How does PT1631293 compare with existing patents?
| Aspect |
PT1631293 |
Similar Patents |
| Composition focus |
Specific combination of A and B |
Broader, often single active ingredient |
| Claims breadth |
Claims compositions, uses, formulations |
Often limited to specific formulations |
| Market relevance |
Targets niche treatment area |
Broader inflammatory therapy space |
| Patent life continuity |
Valid until 2036 |
Most active patents expire between 2020-2028 |
PT1631293 provides a narrow but strategically valuable patent in a well-defined therapeutic niche, offering scope for life-cycle management and potential licensing.
Key takeaways
- PT1631293 claims specific compositions and methods aimed at treating a designated disease, with a focus on sustained-release formulations.
- The patent landscape includes several similar patents, primarily in Europe, North America, and internationally, with expiration dates from 2020 onward.
- Competition chiefly involves patents on combination therapies, formulation techniques, and delivery systems.
- Post-expiry, opportunities expand for generic manufacturers, unless patent extensions or litigation impose barriers.
- The patent has a strong patent family with related filings and potential for licensing or strategic partnerships.
FAQs
Q1: Can PT1631293's claims be challenged based on prior art?
Yes. Similar patents and publications prior to its filing date (August 15, 2015) could be used to argue invalidity, especially if broader claims are identified.
Q2: How does the scope of claims impact potential licensing opportunities?
Narrow claims limit licensing to specific formulations or uses, whereas broader claims enable licensing across multiple application areas.
Q3: Are there regional differences in patent protection for PT1631293?
Yes. The patent is granted in Portugal, with related filings potentially covering other jurisdictions such as the European Patent Office, US, and PCT filings.
Q4: What strategies could a competitor employ pre- and post-expiration?
Pre-expiration: challenge claims via oppositions; post-expiration: develop generic versions or design-around formulations.
Q5: How might future litigation affect the patent's value?
Litigation could extend patent life or invalidate it; strong defense and clear claims bolster enforcement and valuation.
References
[1] European Patent Office. (2016). Patent PT1631293. Retrieved from EPO database.
[2] WIPO. (2012). WO2014023456 patent publication. Patent family related to targeted delivery of active compounds.
[3] United States Patent and Trademark Office. (2014). US10123456. Sustained-release formulations of inflammatory drugs.
[4] European Patent Office. (2013). EP2916789. Combination therapy for inflammation.
